Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 561–570 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 561

    Medicine slug
    eszopiclone
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    63
    Source count
    63
    Agreement rate
    1
    Recorded readings

    1. 52 to 59%

      Numeric value
      52
      Unit
      %
      Source records
      63

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 63 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6022b2f-9b43-40cc-91c7-c224b209efab (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d301b0cf-1492-4be9-83a0-1b64c8fa3b72 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1baa5ba-73ac-462b-a728-217d5992674a (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af86ebdb-e47b-706a-e053-2995a90ad51c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52ab8ee9-a04d-4e27-b0f4-eb050f144715 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2435e2f1-bc52-488f-80e9-f1758e354aae (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c4ff1d6a-918e-c046-e053-2a95a90a9c9b (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10175591-c1b4-461a-830e-8df982d0d2bf (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:edc03482-b013-448a-8cd9-2a17bd6d15e9 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bfa767ce-340b-4d3a-a9c7-0043b6d7ff6e (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7df922bc-5750-4259-906f-64f960c38d5f (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac996f97-fd92-44f8-8bb5-478a81ffb33d (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f4fa6e8-be82-4fb5-9a11-9ba8f557c027 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1582ba77-a4e3-464f-876b-28cc7e41e8f1 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec6ac172-509e-403a-aa0d-4c60010a0035 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e32746a8-6440-4b0a-a445-4467cf0329d5 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd7e4bab-8e25-4788-89e4-6b391f9596fe (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61fd4655-060f-4393-a610-019d8b127058 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:838559f7-4b69-4831-bf50-ab37c6c24c2b (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8ae09eb-4c9b-4560-e053-2995a90a02b1 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b8a09c6-0702-43a7-b47f-a36cd00b7584 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8bb1965e-7845-4c5b-b021-38e251303d68 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9bbf260f-3090-46b5-b3ef-81174697f166 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af86b753-d2ee-9b5f-e053-2a95a90ad23d (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be25bb4e-d84f-4396-a78f-a668a207cf2d (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e261bf7f-1b89-4393-8c48-4e72fc29192f (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00fc3250-3e29-4a4b-ac0c-74910659337c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abe3a610-a25d-4b52-8537-c87e8ba3104a (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3821f4b7-a3c8-4920-ba80-18aa96532c09 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c24ec179-f869-746f-e053-2995a90aa1ff (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9dfe774a-2c7a-4e10-bedd-cde64ad28676 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af86fca8-571a-0cac-e053-2a95a90ae402 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a891ab1-675f-498e-a21e-05964307d2dd (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb972d36-4b2c-45ae-8504-3a16d352dd8b (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57a8450c-59ee-4c96-bef4-308fa7b97d1e (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4832cfbf-a540-46af-bb7d-3ba8e6bc783e (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e04d4f8b-c9a1-4dc9-aac4-2e6376cd9a0c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7832f554-2b82-4ef2-b1ef-266179f271d3 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5451be60-1315-4152-ad13-412e86903c8a (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12593790-e72f-45b1-8895-987cdd075134 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f18cc76f-82aa-4ad7-b8ce-5737733ee104 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b363b90-93dc-1fc1-0501-d140dfc762c7 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4f272eb-02e3-415a-e053-2a95a90a428f (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7bd3e3c-26e9-07e7-e053-2995a90a9ca5 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:923cc646-f22a-4a26-88f7-a19fce016321 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:584dc66c-063a-4552-a056-74b811e2bc80 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:486b760b-7fea-306b-e054-00144ff8d46c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0102ea59-77b1-4e74-83ec-1d205563b55f (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9460be93-cd53-4429-a4d9-2f04e3835168 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af863d89-25db-2893-e053-2a95a90a704c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b39dc64d-adc9-742e-e053-2a95a90ad18b (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af869866-0a11-1a05-e053-2a95a90acdb8 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b5b4fbb-9b86-46c6-9508-37d3d9806dec (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53fcee89-027a-13e5-e054-00144ff8d46c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5469cc59-78f9-447a-9c33-12553bb4073d (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bad8fe65-73c1-4542-8050-720af889905a (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7068c455-691e-4c56-9857-b7b4e13f4784 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fef87d8d-f375-4b00-8765-957ef076bf1a (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52-59%).
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1baa56e5-34d5-c8a1-e063-6394a90ae6c7 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39b96725-2a01-4d9f-a56d-af7491b3b601 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:024f833e-c20c-46a2-971b-3f2a716b1678 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af86fca8-571e-0cac-e053-2a95a90ae402 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45558f0a-83f1-49b9-ab18-f436c0be9677 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is weakly bound to plasma protein (52 to 59%).

  2. Projected row 562

    Medicine slug
    eszopiclone
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    63
    Source count
    63
    Agreement rate
    1
    Recorded readings

    1. 1 hour

      Numeric value
      1
      Unit
      hours
      Source records
      63

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 63 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6022b2f-9b43-40cc-91c7-c224b209efab (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d301b0cf-1492-4be9-83a0-1b64c8fa3b72 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1baa5ba-73ac-462b-a728-217d5992674a (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af86ebdb-e47b-706a-e053-2995a90ad51c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52ab8ee9-a04d-4e27-b0f4-eb050f144715 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2435e2f1-bc52-488f-80e9-f1758e354aae (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c4ff1d6a-918e-c046-e053-2a95a90a9c9b (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10175591-c1b4-461a-830e-8df982d0d2bf (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:edc03482-b013-448a-8cd9-2a17bd6d15e9 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bfa767ce-340b-4d3a-a9c7-0043b6d7ff6e (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7df922bc-5750-4259-906f-64f960c38d5f (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac996f97-fd92-44f8-8bb5-478a81ffb33d (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f4fa6e8-be82-4fb5-9a11-9ba8f557c027 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1582ba77-a4e3-464f-876b-28cc7e41e8f1 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec6ac172-509e-403a-aa0d-4c60010a0035 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e32746a8-6440-4b0a-a445-4467cf0329d5 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd7e4bab-8e25-4788-89e4-6b391f9596fe (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61fd4655-060f-4393-a610-019d8b127058 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:838559f7-4b69-4831-bf50-ab37c6c24c2b (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8ae09eb-4c9b-4560-e053-2995a90a02b1 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b8a09c6-0702-43a7-b47f-a36cd00b7584 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8bb1965e-7845-4c5b-b021-38e251303d68 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9bbf260f-3090-46b5-b3ef-81174697f166 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af86b753-d2ee-9b5f-e053-2a95a90ad23d (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be25bb4e-d84f-4396-a78f-a668a207cf2d (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e261bf7f-1b89-4393-8c48-4e72fc29192f (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00fc3250-3e29-4a4b-ac0c-74910659337c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abe3a610-a25d-4b52-8537-c87e8ba3104a (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3821f4b7-a3c8-4920-ba80-18aa96532c09 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c24ec179-f869-746f-e053-2995a90aa1ff (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9dfe774a-2c7a-4e10-bedd-cde64ad28676 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af86fca8-571a-0cac-e053-2a95a90ae402 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a891ab1-675f-498e-a21e-05964307d2dd (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb972d36-4b2c-45ae-8504-3a16d352dd8b (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57a8450c-59ee-4c96-bef4-308fa7b97d1e (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4832cfbf-a540-46af-bb7d-3ba8e6bc783e (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e04d4f8b-c9a1-4dc9-aac4-2e6376cd9a0c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7832f554-2b82-4ef2-b1ef-266179f271d3 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5451be60-1315-4152-ad13-412e86903c8a (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12593790-e72f-45b1-8895-987cdd075134 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f18cc76f-82aa-4ad7-b8ce-5737733ee104 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b363b90-93dc-1fc1-0501-d140dfc762c7 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4f272eb-02e3-415a-e053-2a95a90a428f (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7bd3e3c-26e9-07e7-e053-2995a90a9ca5 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:923cc646-f22a-4a26-88f7-a19fce016321 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:584dc66c-063a-4552-a056-74b811e2bc80 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:486b760b-7fea-306b-e054-00144ff8d46c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0102ea59-77b1-4e74-83ec-1d205563b55f (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9460be93-cd53-4429-a4d9-2f04e3835168 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af863d89-25db-2893-e053-2a95a90a704c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b39dc64d-adc9-742e-e053-2a95a90ad18b (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af869866-0a11-1a05-e053-2a95a90acdb8 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b5b4fbb-9b86-46c6-9508-37d3d9806dec (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53fcee89-027a-13e5-e054-00144ff8d46c (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5469cc59-78f9-447a-9c33-12553bb4073d (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bad8fe65-73c1-4542-8050-720af889905a (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7068c455-691e-4c56-9857-b7b4e13f4784 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fef87d8d-f375-4b00-8765-957ef076bf1a (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1baa56e5-34d5-c8a1-e063-6394a90ae6c7 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39b96725-2a01-4d9f-a56d-af7491b3b601 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:024f833e-c20c-46a2-971b-3f2a716b1678 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af86fca8-571e-0cac-e053-2a95a90ae402 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45558f0a-83f1-49b9-ab18-f436c0be9677 (opens source in a new tab)

        Eszopiclone label

        Version not recorded · Effective date not recorded

        Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.

  3. Projected row 563

    Medicine slug
    etodolac
    Compared field
    bioavailability
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    73
    Source count
    73
    Agreement rate
    0.808219
    Recorded readings

    1. 100%

      Numeric value
      100
      Unit
      %
      Source records
      59

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 59 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f50a93ca-584a-4205-a79b-31bafdd309c2 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:420b1ed5-e9f2-43dd-8d3c-ca9896221aca (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7d91fcf-7928-4c9e-862b-6922d6e47c9d (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3d865ff0-fc45-1e95-e063-6294a90a8e18 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:188cdd2e-4196-458c-9631-4fa9a0d309b8 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cad9b5ca-a9d4-41d4-aff2-67d0c458aad6 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60cb4de0-ed88-a46b-e053-2a91aa0a8b6d (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da34581d-3066-711c-e053-2995a90a8e84 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1547f132-0d35-45cb-e063-6294a90a2efe (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53160db5-ba48-4cac-afbe-acd608daa0dc (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41bd86b9-2ef3-49a4-874e-fe8ac6891080 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea12933b-2280-4a11-a0e3-554194c53c4d (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86c7b7b8-3a98-e5f4-c558-5b5caede6377 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c783997-6f2a-45ae-b899-c060c8be468a (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74baa6ad-b517-48e2-8cef-d77f5755b279 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:420c7b62-3bea-4d6b-82e0-ab1c176c7f1e (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules is 100% as compared to solution and at least 80% as determined from mass balance studies.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f86d2b22-d3f7-49cd-98f6-cdb2bd855192 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c18497e2-9fca-4500-e053-2a95a90a1bcc (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a355160d-24c3-4a4d-99ea-84c80ce67f90 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules is 100% as compared to solution and at least 80% as determined from mass balance studies.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf17926c-ed90-4fd0-80af-ccee084075e8 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b0d1245-8d01-4fff-9783-cb30c17d9246 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:31a55fb1-9721-4202-af7d-f06074b03102 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06f602d1-6faf-41c8-bcfd-33e51f4ca636 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:113558e6-8b45-cdbd-e063-6394a90ac036 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f306e69-c109-4e60-aaf3-9016a4e2cc33 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf1afcd5-e1da-4874-981f-f252cb0b32c2 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2fef939-2f4a-46ae-8177-073f5e8f57f5 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0fce1aea-5de2-4acb-8a21-2b775c4adb25 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules is 100% as compared to solution and at least 80% as determined from mass balance studies.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbaa1202-1ade-4471-96fb-4b951b386234 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules is 100% as compared to solution and at least 80% as determined from mass balance studies.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7f7c4a4-6245-43e1-af40-fcf61abbc64e (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules is 100% as compared to solution and at least 80% as determined from mass balance studies.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:556a7d5f-2c3c-4efb-ac0c-fca140791602 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e94a98f-d36e-4f28-b79c-6ad8a6793381 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00125d63-d8d0-46c5-bdf1-80d2c85eda5a (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0880f39-a6fa-23ab-e053-2995a90a7eb2 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e7a81661-28a2-40d7-8c90-786629c81e36 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules is 100% as compared to solution and at least 80% as determined from mass balance studies.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:141be3f6-198d-ce46-e063-6294a90a7993 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1149072a-280a-2b11-e063-6394a90ac107 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a38815e-1903-4f03-b83e-9780c71d4971 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c74c3c56-a5ac-40b4-974b-c4f4b05c5df9 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03458123-e27c-4447-9ef3-3bd32481cb97 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12f0685b-2127-d0d6-e063-6394a90a62d1 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be53bc5c-4294-44a7-b28c-7db3f925396d (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d682f98-1e8a-4c2b-6df3-169d2ed10dc1 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d583988c-3e7e-4415-b2fd-34049791cd1c (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules is 100% as compared to solution and at least 80% as determined from mass balance studies.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:556eaa67-d30d-4095-a981-c65f98d3acdd (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cdde46e5-1123-410f-aafc-0c6e904a5d5b (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2425aef0-57eb-d1a5-e063-6294a90a0bf2 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80e9d756-9278-48bb-bfdd-7d070ae0f341 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d392c1b-95c2-4925-98bf-0203c412d3da (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules is 100% as compared to solution and at least 80% as determined from mass balance studies.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ec87ffd-057e-420c-b8f2-0a6eed4152be (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:117b3005-a8ec-4f76-824c-95ec42dc87a1 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55ae2e78-d803-496b-b66d-af1140312785 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:007c55fa-ef8b-4a8e-bfe5-e47c6e5da727 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec82b108-6a6f-4d1b-82cb-831d4ed36c80 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d83d9f30-c367-f8b3-e053-2a95a90a1f40 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:479bce92-2066-46ed-b4bb-8c7a59edfffd (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from mass balance studies.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:336d5331-4d60-42e2-8cfc-aad57c01eda0 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac tablet is 100% as compared to solution and at least 80% as determined from mass balance studies.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:301087e4-f05c-4fd3-8815-c86c6f12ff61 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules is 100% as compared to solution and at least 80% as determined from mass balance studies.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18215cb7-c833-4a98-a61d-4bedf518a380 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies.

    2. 80%

      Numeric value
      80
      Unit
      %
      Source records
      14

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 14 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c5b44b4-78d5-43b2-827d-d2763b6672b3 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Mean (CV)% % Coefficient of variation Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-Release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (T max ), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t½), h 6.4 (22%) 8.4 (30%)
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a040d8e-8d0c-442f-b4e5-161aa7ccbe9a (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Mean (CV)% % Coefficient of variation Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-Release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (T max ), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t 1/2 ), h 6.4 (22%) 8.4 (
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27e98e6d-9fad-3a94-e063-6394a90a1dcb (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Table 1 * % Coefficient of variation Mean (CV)% * Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (T max ), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t 1/2 ), h 6.4
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6761e6b1-2399-4643-e053-2991aa0a6f17 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Table 1 * % Coefficient of variation Mean (CV)% * Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (T max ), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t 1/2 ), h 6.4
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f3bf1675-8fda-40d3-8427-0a6a6133a3d3 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Mean (CV)%1 Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-Release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (T max ), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t 1/2 ), h 6.4 (22%) 8.4 (30%) 1 % Coefficient of va
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e4824cc-4d52-4f20-9674-cfcb9ee66574 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Table 1 * % Coefficient of variation Mean (CV)% * Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (T max ), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t 1/2 ), h 6.4
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:449b273a-936a-4c49-b0c8-d0daa47733ae (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Mean (CV)% % Coefficient of variation Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-Release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (T max ), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t ½ ), h 6.4 (22%) 8.4 (30
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ef79e43-0628-4795-937e-ebb752d79133 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Table 1 * % Coefficient of variation Mean (CV)% * Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (T max ), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t 1/2 ), h 6.4
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:baebdfb2-17f6-9081-e053-2a95a90ab331 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Mean (CV)%* Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-Release Tablets *% Coefficient of variation Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (Tmax), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t½), h 6.4 (22%) 8.4 (30%)
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c59c5108-a09b-2a03-e053-2995a90abba1 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Mean (CV)% % Coefficient of variation Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-Release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (T max ), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t½), h 6.4 (22%) 8.4 (30%)
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15d6bc8e-1e25-6676-e063-6294a90a0035 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Table 1 Mean ( CV )% % Coefficient of variation Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended - release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (Tmax), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t1/2), h 6.4 (22
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4712e069-83b6-4052-8d95-f59ab1dba744 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Table 1 Mean (CV)% % Coefficient of variation Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (Tmax), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t1/2), h 6.4 (22%) 8
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d294d541-3049-6bfe-e053-2995a90a23ea (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Mean (CV)% * Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-Release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (Tmax), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t½), h 6.4 (22%) 8.4 (30%) * % Coefficient of variati
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:107ea9d7-80a9-41a4-b61e-168370127319 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        Mean (CV)% % Coefficient of variation Pharmacokinetic Parameters Etodolac Tablets Etodolac Extended-Release Tablets Extent of Oral Absorption (Bioavailability) [F] ≥ 80% ≥ 80% Time to Peak Concentration (T max ), h 1.4 (61%) 6.7 (47%) Oral Clearance (CL/F), mL/h/kg 49.1 (33%) 46.8 (37%) Apparent Volume of Distribution (Vd/F), mL/kg 393 (29%) 566 (26%) Terminal Half-Life (t½), h 6.4 (22%) 8.4 (30%)

  4. Projected row 564

    Medicine slug
    etodolac
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    73
    Source count
    59
    Agreement rate
    1
    Recorded readings

    1. 6.4 hours

      Numeric value
      6.4
      Unit
      hours
      Source records
      59

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 59 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f50a93ca-584a-4205-a79b-31bafdd309c2 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:420b1ed5-e9f2-43dd-8d3c-ca9896221aca (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7d91fcf-7928-4c9e-862b-6922d6e47c9d (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3d865ff0-fc45-1e95-e063-6294a90a8e18 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:188cdd2e-4196-458c-9631-4fa9a0d309b8 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cad9b5ca-a9d4-41d4-aff2-67d0c458aad6 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60cb4de0-ed88-a46b-e053-2a91aa0a8b6d (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da34581d-3066-711c-e053-2995a90a8e84 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1547f132-0d35-45cb-e063-6294a90a2efe (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53160db5-ba48-4cac-afbe-acd608daa0dc (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41bd86b9-2ef3-49a4-874e-fe8ac6891080 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea12933b-2280-4a11-a0e3-554194c53c4d (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86c7b7b8-3a98-e5f4-c558-5b5caede6377 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c783997-6f2a-45ae-b899-c060c8be468a (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74baa6ad-b517-48e2-8cef-d77f5755b279 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:420c7b62-3bea-4d6b-82e0-ab1c176c7f1e (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f86d2b22-d3f7-49cd-98f6-cdb2bd855192 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal halflife (t ½ ) of etodolac is 6.4 hours (22% CV).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c18497e2-9fca-4500-e053-2a95a90a1bcc (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t1/2) of etodolac is 6.4 hours (22% CV).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a355160d-24c3-4a4d-99ea-84c80ce67f90 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf17926c-ed90-4fd0-80af-ccee084075e8 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b0d1245-8d01-4fff-9783-cb30c17d9246 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:31a55fb1-9721-4202-af7d-f06074b03102 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06f602d1-6faf-41c8-bcfd-33e51f4ca636 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:113558e6-8b45-cdbd-e063-6394a90ac036 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f306e69-c109-4e60-aaf3-9016a4e2cc33 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf1afcd5-e1da-4874-981f-f252cb0b32c2 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal halflife (t ½ ) of etodolac is 6.4 hours (22% CV).
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2fef939-2f4a-46ae-8177-073f5e8f57f5 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0fce1aea-5de2-4acb-8a21-2b775c4adb25 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbaa1202-1ade-4471-96fb-4b951b386234 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7f7c4a4-6245-43e1-af40-fcf61abbc64e (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:556a7d5f-2c3c-4efb-ac0c-fca140791602 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e94a98f-d36e-4f28-b79c-6ad8a6793381 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00125d63-d8d0-46c5-bdf1-80d2c85eda5a (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0880f39-a6fa-23ab-e053-2995a90a7eb2 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e7a81661-28a2-40d7-8c90-786629c81e36 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:141be3f6-198d-ce46-e063-6294a90a7993 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1149072a-280a-2b11-e063-6394a90ac107 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a38815e-1903-4f03-b83e-9780c71d4971 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c74c3c56-a5ac-40b4-974b-c4f4b05c5df9 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03458123-e27c-4447-9ef3-3bd32481cb97 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12f0685b-2127-d0d6-e063-6394a90a62d1 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be53bc5c-4294-44a7-b28c-7db3f925396d (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d682f98-1e8a-4c2b-6df3-169d2ed10dc1 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d583988c-3e7e-4415-b2fd-34049791cd1c (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:556eaa67-d30d-4095-a981-c65f98d3acdd (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cdde46e5-1123-410f-aafc-0c6e904a5d5b (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2425aef0-57eb-d1a5-e063-6294a90a0bf2 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80e9d756-9278-48bb-bfdd-7d070ae0f341 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d392c1b-95c2-4925-98bf-0203c412d3da (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ec87ffd-057e-420c-b8f2-0a6eed4152be (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:117b3005-a8ec-4f76-824c-95ec42dc87a1 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55ae2e78-d803-496b-b66d-af1140312785 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:007c55fa-ef8b-4a8e-bfe5-e47c6e5da727 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec82b108-6a6f-4d1b-82cb-831d4ed36c80 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d83d9f30-c367-f8b3-e053-2a95a90a1f40 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t½) of etodolac is 6.4 hours (22% CV).
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:479bce92-2066-46ed-b4bb-8c7a59edfffd (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:336d5331-4d60-42e2-8cfc-aad57c01eda0 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:301087e4-f05c-4fd3-8815-c86c6f12ff61 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t 1/2 ) of etodolac is 6.4 hours (22% CV).
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18215cb7-c833-4a98-a61d-4bedf518a380 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        The terminal half-life (t ½ ) of etodolac is 6.4 hours (22% CV).

  5. Projected row 565

    Medicine slug
    etodolac
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    73
    Source count
    14
    Agreement rate
    1
    Recorded readings

    1. 6 hours

      Numeric value
      6
      Unit
      hours
      Source records
      14

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 14 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c5b44b4-78d5-43b2-827d-d2763b6672b3 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a040d8e-8d0c-442f-b4e5-161aa7ccbe9a (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27e98e6d-9fad-3a94-e063-6394a90a1dcb (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6761e6b1-2399-4643-e053-2991aa0a6f17 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f3bf1675-8fda-40d3-8427-0a6a6133a3d3 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e4824cc-4d52-4f20-9674-cfcb9ee66574 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:449b273a-936a-4c49-b0c8-d0daa47733ae (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ef79e43-0628-4795-937e-ebb752d79133 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:baebdfb2-17f6-9081-e053-2a95a90ab331 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c59c5108-a09b-2a03-e053-2995a90abba1 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15d6bc8e-1e25-6676-e063-6294a90a0035 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4712e069-83b6-4052-8d95-f59ab1dba744 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d294d541-3049-6bfe-e053-2995a90a23ea (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:107ea9d7-80a9-41a4-b61e-168370127319 (opens source in a new tab)

        Etodolac label

        Version not recorded · Effective date not recorded

        After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.

  6. Projected row 566

    Medicine slug
    etoposide
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    12
    Source count
    4
    Agreement rate
    1
    Recorded readings

    1. 50%

      Numeric value
      50
      Unit
      %
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a40f3ed-4a36-4616-af6c-b616140fd5ee (opens source in a new tab)

        Etoposide label

        Version not recorded · Effective date not recorded

        The overall mean value of oral capsule bioavailability is approximately 50% (range, 25% to 75%).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe870629-104d-4d67-a7c6-f53bc588121e (opens source in a new tab)

        Etoposide label

        Version not recorded · Effective date not recorded

        The overall mean value of oral capsule bioavailability is approximately 50% (range 25 to 75%).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:508a418e-985f-4208-9324-2230655bb5c2 (opens source in a new tab)

        Etoposide label

        Version not recorded · Effective date not recorded

        The overall mean value of oral capsule bioavailability is approximately 50% (range 25% to 75%).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bc994df-ee84-4ed7-80fa-737f70918953 (opens source in a new tab)

        Etoposide label

        Version not recorded · Effective date not recorded

        The overall mean value of oral capsule bioavailability is approximately 50% (range, 25% to 75%).

  7. Projected row 567

    Medicine slug
    etoposide
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    12
    Source count
    2
    Agreement rate
    0.5
    Recorded readings

    1. 4 hours

      Numeric value
      4
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:acc1e443-ef7b-486f-a638-710a20e81059 (opens source in a new tab)

        Etoposide label

        Version not recorded · Effective date not recorded

        Elimination Etoposide elimination half-life is 4 hours to 11 hours.

    2. 4 to 11 hours

      Numeric value
      4
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7499fc35-fae8-44ad-bbab-9a1a589bf3ee (opens source in a new tab)

        Etoposide label

        Version not recorded · Effective date not recorded

        Elimination The terminal elimination half-life of etoposide ranges from 4 to 11 hours.

  8. Projected row 568

    Medicine slug
    etoposide
    Compared field
    volumeOfDistribution
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    12
    Source count
    2
    Agreement rate
    0.5
    Recorded readings

    1. 18 to 29 liters

      Numeric value
      18
      Unit
      L
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7499fc35-fae8-44ad-bbab-9a1a589bf3ee (opens source in a new tab)

        Etoposide label

        Version not recorded · Effective date not recorded

        Distribution Following administration of an injectable etoposide formulation, the mean volume of distribution of etoposide at steady state was 18 to 29 liters.

    2. 7 L

      Numeric value
      7
      Unit
      L
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:acc1e443-ef7b-486f-a638-710a20e81059 (opens source in a new tab)

        Etoposide label

        Version not recorded · Effective date not recorded

        Distribution Etoposide mean volume of distribution at steady state is 7 L/m 2 to 17 L/m 2 .

  9. Projected row 569

    Medicine slug
    etravirine
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    7
    Agreement rate
    1
    Recorded readings

    1. 99.6%

      Numeric value
      99.6
      Unit
      %
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a9cbc29-9f15-4b24-8d86-206b82887f3d (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Distribution Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) in vitro .
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:154b621d-9a72-489f-9127-55f9bf1797a0 (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Distribution Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) in vitro .
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea3856f6-fedf-ee88-e053-2a95a90a33ce (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Distribution Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) in vitro .
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48ffeac8-38e8-4007-903a-dbffce25d679 (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Distribution Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) in vitro .
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:458bb39e-2e87-b4b4-e063-6394a90ae867 (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Distribution Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) in vitro .
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4e009f19-4609-4020-bee1-dc27c504046c (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Distribution Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) in vitro .
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50ca19cb-0f43-4d7b-8c9e-8b3aaded0546 (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Distribution Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) in vitro .

  10. Projected row 570

    Medicine slug
    etravirine
    Compared field
    tMax
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    7
    Source count
    7
    Agreement rate
    0.857143
    Recorded readings

    1. 2.5 to 4 hours

      Numeric value
      2.5
      Unit
      hours
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a9cbc29-9f15-4b24-8d86-206b82887f3d (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Absorption and Bioavailability Following oral administration, etravirine was absorbed with a T max of about 2.5 to 4 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:154b621d-9a72-489f-9127-55f9bf1797a0 (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Absorption and Bioavailability Following oral administration, Etravirine was absorbed with a T max of about 2.5 to 4 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea3856f6-fedf-ee88-e053-2a95a90a33ce (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Absorption and Bioavailability Following oral administration, etravirine was absorbed with a T max of about 2.5 to 4 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48ffeac8-38e8-4007-903a-dbffce25d679 (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Absorption and Bioavailability Following oral administration, Etravirine was absorbed with a T max of about 2.5 to 4 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4e009f19-4609-4020-bee1-dc27c504046c (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Absorption and Bioavailability Following oral administration, etravirine was absorbed with a T max of about 2.5 to 4 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50ca19cb-0f43-4d7b-8c9e-8b3aaded0546 (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Absorption and Bioavailability Following oral administration, etravirine was absorbed with a T max of about 2.5 to 4 hours.

    2. 2.5 hours

      Numeric value
      2.5
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:458bb39e-2e87-b4b4-e063-6394a90ae867 (opens source in a new tab)

        Etravirine label

        Version not recorded · Effective date not recorded

        Absorption and Bioavailability Following oral administration, etravirine was absorbed with a T max of about 2.5 hours to 4 hours.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=560

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy